嗜中性白血球低下症市場規模、佔有率和成長分析（按治療類型、風險因子、藥物類別和地區分類）－2026-2033年產業預測

預計到 2024 年，全球嗜中性白血球低下症市場規模將達到 125.5 億美元，到 2025 年將達到 132.4 億美元，到 2033 年將達到 203.3 億美元，在預測期（2026-2033 年）內複合成長率為 5.5%。

發燒性嗜中性白血球低下症市場受多種關鍵因素驅動，包括全球癌症發生率上升、化療使用增加以及長效粒細胞集落刺激因子（G-CSF）療法的進展。此外，生物相似藥的廣泛應用提高了治療可近性，而對支持治療指南的認知不斷提高，也促進了早期療育，從而降低了住院率。然而，挑戰依然存在，例如生物相似藥的高成本限制了中低收入社區的用藥。缺乏認知和診斷延遲可能導致併發症和住院治療。同時，長期使用G-CSF引發了人們對副作用和抗菌素抗藥性的擔憂。此外，某些市場對生物相似藥核准的監管不確定性阻礙了患者獲得價格合理的治療，從而限制了整體市場成長。

嗜中性白血球低下症市場促進因素

全球癌症發生率的上升顯著增加了嗜中性白血球低下症的風險，尤其是在接受化療的患者身上。癌症病例的激增推動了發燒性嗜嗜中性白血球低下症症市場的擴張，這主要得益於人們對該疾病的認知不斷提高，以及對早期診斷和支持性治療（例如粒細胞集落刺激因子[G-CSF]）的需求不斷成長。此外，腫瘤治療路徑中早期療育療法的顯著增加也促進了市場成長。隨著醫療保健相關人員將有效管理嗜中性白血球低下症列為優先事項，市場格局也不斷演變以滿足這些不斷變化的需求。

限制嗜中性白血球低下症市場的因素

全球發燒性嗜嗜中性白血球低下症市場面臨許多限制因素，尤其是在中低收入國家，患者難以承擔生物製藥治療的經濟負擔。保險覆蓋不足和高昂的自付費用加劇了這項挑戰，導致患者無法及時接受治療。這些經濟負擔構成了嚴重的就醫障礙，造成治療差異，並對患者預後產生負面影響。因此，這些地區嗜中性白血球低下症症的整體預後受到醫療系統資金籌措限制的影響，凸顯了增加資金和資源以改善患者照護和獲得必要治療的必要性。

嗜中性白血球低下症市場趨勢

全球發燒性嗜嗜中性白血球低下症市場正經歷顯著的變革時期，這主要得益於生物相似藥在癌症支持治療領域日益廣泛的應用。諸如Filgrastim和Pegfilgrastim等產品正迅速發展，顯著降低了治療成本，從而提高了患者（尤其是在發展中地區）獲得治療的機會。這一趨勢正在推動全球癌症治療的公平性，確保患者無論經濟狀況如何都能獲得所需的治療。此外，生物相似藥的引入促進了供應商之間的良性競爭，推動了創新並改善了治療選擇。因此，嗜中性白血球低下症的治療格局正在快速演變，這反映了全球範圍內實現全面患者照護的積極方向。

目錄

介紹

• 調查目標
• 調查範圍
• 定義

調查方法

• 資訊收集
• 二手資料和一手資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分市場機會分析

市場動態與展望

• 市場規模
• 市場動態
  • 促進因素和機遇
  • 限制與挑戰
• 波特分析

關鍵市場考察

• 關鍵成功因素
• 競爭程度
• 關鍵投資機會
• 市場生態系統
• 市場吸引力指數（2025）
• PESTEL 分析
• 總體經濟指標
• 價值鏈分析
• 定價分析

嗜中性白血球低下症市場規模（按治療類型和複合年成長率分類）（2026-2033 年）

• 預防性治療
• 治療

全球嗜中性白血球低下症市場規模（按風險因子和複合年成長率分類）（2026-2033 年）

• 化療引起的嗜中性白血球低下症
• 移植相關性嗜中性白血球低下症
• 遺傳性疾病

嗜中性白血球低下症市場規模（按藥物類別和複合年成長率分類）（2026-2033 年）

• 抗生素
• 顆粒細胞增生因子
• 抗真菌藥物
• 抗病毒藥物

嗜中性白血球低下症市場規模及複合年成長率（2026-2033）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 亞太其他地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地區
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前五大公司對比
• 主要企業的市場定位（2025 年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市佔率分析（2025 年）
• 主要企業公司簡介
  • 公司詳情
  • 產品系列分析
  • 依業務板塊進行公司股票分析
  • 2023-2025年營收年比比較

主要企業簡介

• Amgen Inc.（USA）
• Pfizer Inc.（USA）
• Novartis AG（Switzerland）
• Teva Pharmaceutical Industries Ltd.（Israel）
• Viatris Inc.（USA）
• Biocon Biologics Ltd（India）
• Coherus BioSciences, Inc.（USA）
• Kyowa Kirin Co., Ltd.（Japan）
• Spectrum Pharmaceuticals, Inc.（USA）
• Hanmi Pharmaceutical Co., Ltd.（South Korea）
• BeyondSpring Inc.（USA）
• G1 Therapeutics, Inc.（USA）
• Partner Therapeutics, Inc.（USA）
• Cellerant Therapeutics, Inc.（USA）
• Fresenius Kabi（Germany）
• Intas Pharmaceuticals Ltd.（India）
• Gedeon Richter Plc.（Hungary）
• Aurobindo Pharma Limited（India）
• Amneal Pharmaceuticals, Inc.（USA）
• Merck & Co., Inc.（USA）

結論與建議

Global Febrile Neutropenia Market size was valued at USD 12.55 Billion in 2024 and is poised to grow from USD 13.24 Billion in 2025 to USD 20.33 Billion by 2033, growing at a CAGR of 5.5% during the forecast period (2026-2033).

The febrile neutropenia market is driven by several key factors, including the rising incidence of cancer worldwide, increased chemotherapy utilization, and advancements in long-acting G-CSF therapies. Additionally, the growing availability of biosimilars has enhanced treatment access, while awareness of supportive care guidelines promotes early intervention, consequently reducing hospitalization rates. However, challenges persist, such as the high costs associated with biosimilar medications, which limit accessibility in lower and middle-income regions. Low awareness and late diagnoses lead to complications that necessitate hospitalization, while the chronic use of G-CSFs raises concerns over side effects and antibiotic resistance. Furthermore, regulatory uncertainties regarding biosimilar approvals in certain markets hinder the accessibility of affordable treatments, posing constraints to overall market growth.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Febrile Neutropenia market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Febrile Neutropenia Market Segments Analysis

Global Febrile Neutropenia Market is segmented by Treatment Type, Risk Factors, Drug Class and region. Based on Treatment Type, the market is segmented into Prophylactic Treatment and Therapeutic Treatment. Based on Risk Factors, the market is segmented into Chemotherapy-Induced Neutropenia, Transplant-Related Neutropenia and Genetic Disorders. Based on Drug Class, the market is segmented into Antibiotics, Granulocyte Colony-Stimulating Factors, Antifungals and Antivirals. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Febrile Neutropenia Market

The rising incidence of cancer globally has significantly heightened the risk of febrile neutropenia, especially in patients undergoing chemotherapy. This surge in cancer cases has contributed to the expansion of the febrile neutropenia market, driven by a growing awareness of the condition and an increasing demand for early diagnosis and supportive treatments like G-CSFs. Additionally, there is a notable shift towards earlier intervention therapies within oncology treatment pathways, which further supports market growth. As healthcare stakeholders prioritize effective management of febrile neutropenia, the overall market landscape continues to evolve in response to these changing needs.

Restraints in the Global Febrile Neutropenia Market

The global febrile neutropenia market faces significant constraints, particularly in low and middle-income countries, where patients struggle with the financial implications of biologic therapies. The challenge is exacerbated by inadequate insurance coverage and high out-of-pocket expenses, which can deter individuals from seeking timely treatment. This economic strain creates substantial barriers to access and leads to treatment gaps that adversely affect patient outcomes. Consequently, the overall prognosis for febrile neutropenia in these regions is influenced by the limitations of funding within healthcare systems, highlighting the need for improved financial support and resources to enhance patient care and access to necessary therapies.

Market Trends of the Global Febrile Neutropenia Market

The Global Febrile Neutropenia market is witnessing a significant shift driven by the increasing adoption of biosimilars in supportive cancer care. Products like filgrastim and pegfilgrastim are gaining momentum, providing essential cost-saving benefits that enhance treatment accessibility, particularly in developing regions. This trend fosters equitable cancer care on a global scale, ensuring that patients receive necessary therapies regardless of their financial background. Additionally, the introduction of biosimilars stimulates healthy competition among providers, driving innovation and improving treatment options. As a result, the febrile neutropenia landscape is evolving rapidly, reflecting a positive trajectory towards comprehensive patient care worldwide.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Febrile Neutropenia Market Size by Treatment Type & CAGR (2026-2033)

• Market Overview
• Prophylactic Treatment
• Therapeutic Treatment

Global Febrile Neutropenia Market Size by Risk Factors & CAGR (2026-2033)

• Market Overview
• Chemotherapy-Induced Neutropenia
• Transplant-Related Neutropenia
• Genetic Disorders

Global Febrile Neutropenia Market Size by Drug Class & CAGR (2026-2033)

• Market Overview
• Antibiotics
• Granulocyte Colony-Stimulating Factors
• Antifungals
• Antivirals

Global Febrile Neutropenia Market Size & CAGR (2026-2033)

• North America (Treatment Type, Risk Factors, Drug Class)
  • US
  • Canada
• Europe (Treatment Type, Risk Factors, Drug Class)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Treatment Type, Risk Factors, Drug Class)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Treatment Type, Risk Factors, Drug Class)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Treatment Type, Risk Factors, Drug Class)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Amgen Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Viatris Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biocon Biologics Ltd (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Coherus BioSciences, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kyowa Kirin Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Spectrum Pharmaceuticals, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hanmi Pharmaceutical Co., Ltd. (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BeyondSpring Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• G1 Therapeutics, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Partner Therapeutics, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cellerant Therapeutics, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Fresenius Kabi (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Intas Pharmaceuticals Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gedeon Richter Plc. (Hungary)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aurobindo Pharma Limited (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amneal Pharmaceuticals, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations